Alliance Wealth Advisors (Utah)’s Amneal Pharmaceuticals AMRX Stock Holding History

Alliance Wealth Advisors (Utah)’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$233K	Buy	+13,439	New	+$184K	0.04%	219

Other funds holding AMRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Alliance Wealth Advisors (Utah)'s AMRX Position: Q2 2026 in Review

Alliance Wealth Advisors (Utah) opened a new position in Amneal Pharmaceuticals (AMRX) in Q2 2026: 13,439 shares worth $233K. The stake represents 0.04% of the portfolio and ranks #219 among its holdings.

311 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

Alliance Wealth Advisors (Utah) held 13,439 shares of Amneal Pharmaceuticals worth $233K as of Q2 2026.
Amneal Pharmaceuticals was a new Alliance Wealth Advisors (Utah) position in Q2 2026.
Amneal Pharmaceuticals made up 0.04% of Alliance Wealth Advisors (Utah)'s portfolio in Q2 2026, its #219 holding.
311 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Alliance Wealth Advisors (Utah)'s 13F filing for Q2 2026, filed 23 Jul 2026.